Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice

Overview of attention for article published in Frontiers in Pharmacology, October 2022

Altmetric Badge

Mentioned by

So far, Dimensions has found 6 publications that cite this research output.

Article in Journal of Clinical Medicine (February 2024)

Article in Frontiers in Cardiovascular Medicine (February 2024)

Preprint in Research Square (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.